XML 48 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2012
Mar. 31, 2019
Mar. 31, 2018
Loss Contingencies [Line Items]      
Rent expense under operating lease agreements   $ 400 $ 400
Operating Lease expense   400  
Variable executory cost   300  
Research and development expense   1,583 $ 3,286
Tissue Processor Sub License Agreement [Member]      
Loss Contingencies [Line Items]      
Research and development expense   700  
Reimbursement for development cost $ 300    
Additional non-refundable royalty fee   $ 30  
Additional non-refundable royalty fee payment description   2016 through 2019  
Potential milestone payment   $ 10,200  
Minimum [Member] | Tissue Processor Sub License Agreement [Member]      
Loss Contingencies [Line Items]      
Additional non-refundable royalty fee   20  
Hydrogel License Agreement [Member]      
Loss Contingencies [Line Items]      
Research and development expense   3,200  
Amount to be paid upon FDA approval   3,000  
Tissue Regeneration License Agreement [Member]      
Loss Contingencies [Line Items]      
Research and development expense   800  
Amount to be paid upon FDA approval   $ 300  
Percentage of royalty offsetting   50.00%  
Tissue Regeneration License Agreement [Member] | Minimum [Member]      
Loss Contingencies [Line Items]      
Non-refundable royalty fee   $ 10